featured
ASCO 2015 Recap: Dr. Bradley Somer on RCC—Part 1
- Interview by
-
Jarushka
Naidoo
MD
- Interview with
-
Bradley
G.
Somer
MD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Motzer R, Hutson T, Glen H, et al Randomized phase II, three-arm trial of lenvatinib [LEN], everolimus [EVE], and LEN+EVE in patients with metastatic renal cell carcinoma. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4506.
- Motzer R, Alyasova A, Dingwei Ye D, et al.RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC). Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4518.
- Choueiri TK, Fishman MN, Escudier B, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4500.
Disclosure statements are available on the authors' profiles:
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.